Evidence map›Paper›PMID 34874815›Full record

Trial reportAmerican journal of respiratory and critical care medicine2022

Prospective Identification of Subclinical Interstitial Lung Disease in a Rheumatoid Arthritis Cohort Is Associated with the

Scott M Matson, Kevin D Deane, Anna L Peljto, Tami J Bang, Peter B Sachs, Avram D Walts, Christopher Collora, Shuyu Ye, M Kristen Demoruelle, Stephen M Humphries and 2 more

Open access · greenAbstract readClinical TrialLetter
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Lung disease in rheumatoid arthritis.Nature reviews. Rheumatology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Genomic and Serological Rheumatoid Arthritis Biomarkers,Annals of the American Thoracic Society · 2025
    Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Scott M MatsonUniversity of Kansas School of Medicine Kansas City, Kansas.
Kevin D DeaneUniversity of Colorado School of Medicine Aurora, Colorado.
Anna L PeljtoUniversity of Colorado School of Medicine Aurora, Colorado.
Tami J BangUniversity of Colorado School of Medicine Aurora, Colorado.
Peter B SachsUniversity of Colorado School of Medicine Aurora, Colorado.
Avram D WaltsUniversity of Colorado School of Medicine Aurora, Colorado.
Christopher ColloraUniversity of Colorado School of Medicine Aurora, Colorado.
Shuyu YeUniversity of Colorado School of Medicine Aurora, Colorado.
M Kristen DemoruelleUniversity of Colorado School of Medicine Aurora, Colorado.
Stephen M HumphriesNational Jewish Health Denver, Colorado.ORCID 0000-0002-5113-4530
David A SchwartzUniversity of Colorado School of Medicine Aurora, Colorado.
Joyce S LeeUniversity of Colorado School of Medicine Aurora, Colorado.ORCID 0000-0002-5758-8365
University of Colorado Denver · USNational Jewish Health · USUniversity of Kansas · US

Funding

MULTIDISCIPLINARY RESPIRATORY DISEASES RESEARCH TRAININGT32HL007085 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ELLEN L BURNHAM, LISA A MAIER · 1985 to 2026
$21.6M
Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Devin Charles Koestler · 2019 to 2026
$21.5M
Preclinical Pulmonary Fibrosis, an opportune rare disease cohortUH3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2022 to 2025
$4.3M
Genes and Transcripts that Interact with MUC5B in Pulmonary FibrosisR01HL149836 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI CLOUTHIER, DAVID E., SCHWARTZ, DAVID ALBERT · 2020 to 2023
$3.0M
Rheumatoid Arthritis Patients at Risk for Interstitial Lung DiseaseK23HL138131 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI LEE, JOYCE SUJIN · 2017 to 2019
$576k
lncRNAs, Linking Genetic Susceptibility to Molecular Phenotype in IPFI01BX005295 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI David Albert Schwartz · 2022 to 2026
–
BLRD VA I01 BX005295NHLBI NIH HHS K23 HL138131NHLBI NIH HHS R01 HL149836NHLBI NIH HHS T32 HL007085NHLBI NIH HHS UH3 HL151865NIGMS NIH HHS P20 GM130423
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Genetic Predisposition to DiseaseAdultAgedArthritis, RheumatoidEarly DiagnosisFemaleGenetic MarkersHumansLung Diseases, InterstitialMaleMiddle AgedMucin-5BMutationPrevalenceProspective StudiesGenetic MarkersMUC5B protein, humanMucin-5B

Identifiers

PMID34874815
PMCPMC8886943
OpenAlexW4200242381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.